Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-01-29
2008-01-29
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S134100, C424S135100, C424S141100, C424S143100, C424S144100, C424S152100, C424S153100, C424S172100, C424S173100, C424S185100, C424S192100, C514S002600, C514S008100, C514S015800, C514S863000, C514S885000
Reexamination Certificate
active
07323171
ABSTRACT:
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
REFERENCES:
patent: 4579844 (1986-04-01), Rovee et al.
patent: 4681760 (1987-07-01), Fathman
patent: 4738297 (1988-04-01), Takagi et al.
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4833092 (1989-05-01), Geysen
patent: 4956281 (1990-09-01), Wallner et al.
patent: 5047336 (1991-09-01), Cate et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5122514 (1992-06-01), Boger et al.
patent: 5185441 (1993-02-01), Wallner et al.
patent: 5190859 (1993-03-01), Dustin et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5547853 (1996-08-01), Wallner et al.
patent: 5556943 (1996-09-01), Yamashita et al.
patent: 5565335 (1996-10-01), Capon et al.
patent: 5728677 (1998-03-01), Wallner et al.
patent: 5730979 (1998-03-01), Bazin et al.
patent: 5817311 (1998-10-01), Bazin et al.
patent: 5914111 (1999-06-01), Wallner et al.
patent: 5928643 (1999-07-01), Wallner et al.
patent: 5951983 (1999-09-01), Bazin et al.
patent: 5952499 (1999-09-01), Whittaker et al.
patent: 6117655 (2000-09-01), Capon et al.
patent: 6162432 (2000-12-01), Wallner et al.
patent: 6270766 (2001-08-01), Feldman et al.
patent: 6337337 (2002-01-01), Buck
patent: 6384198 (2002-05-01), Diegel et al.
patent: 6764681 (2004-07-01), Wallner et al.
patent: 2002/0009446 (2002-01-01), Magilavy
patent: 2003/0044406 (2003-03-01), Dingivan
patent: 2003/0185824 (2003-10-01), Vaishnow et al.
patent: 2120500 (1993-04-01), None
patent: 1326940 (1994-02-01), None
patent: 1338078 (1996-02-01), None
patent: 0 200 412 (1986-12-01), None
patent: 280 578 (1988-02-01), None
patent: 0 260 880 (1988-03-01), None
patent: 0 314 317 (1989-03-01), None
patent: 0 325 266 (1989-07-01), None
patent: 0 345 466 (1989-12-01), None
patent: 0 368 684 (1990-05-01), None
patent: 0 503 646 (1992-09-01), None
patent: 0 503 648 (1992-09-01), None
patent: 0 517 174 (1992-12-01), None
patent: 0 325 262 (1994-03-01), None
patent: 0 626 447 (1994-11-01), None
patent: 0 607 332 (1997-12-01), None
patent: 1 637 155 (2006-03-01), None
patent: 63-233917 (1988-09-01), None
patent: 2-501113 (1990-04-01), None
patent: 1-502875 (1990-10-01), None
patent: 2-503269 (1990-10-01), None
patent: 7-502495 (1995-03-01), None
patent: WO 88/06592 (1988-09-01), None
patent: WO88/07089 (1988-09-01), None
patent: WO 88/09820 (1988-12-01), None
patent: WO 89/02922 (1989-04-01), None
patent: WO89/07452 (1989-08-01), None
patent: WO 90/02181 (1990-03-01), None
patent: WO 90/07517 (1990-07-01), None
patent: WO 90/08187 (1990-07-01), None
patent: WO90/09195 (1990-08-01), None
patent: WO 90/12099 (1990-10-01), None
patent: WO91/07987 (1991-06-01), None
patent: WO91/10741 (1991-07-01), None
patent: WO 91/11194 (1991-08-01), None
patent: WO 91/11461 (1991-08-01), None
patent: WO 92/07581 (1992-05-01), None
patent: WO 93/06852 (1993-04-01), None
patent: WO 93/06866 (1993-04-01), None
patent: WO 95/24217 (1995-09-01), None
patent: WO 98/05357 (1998-02-01), None
patent: WO 02/060480 (2002-08-01), None
patent: WO 03/009740 (2003-02-01), None
The Interferons: Basic Biology and Therapeutic Potential by Ezekowitz et al. in Therapeutic Immunology, edited by Austen et al., Blackwell Science, Cambridge, MA, 1996; see pgs. 249-263.
Albert-Wolf et al., “Immunomodulatory Properties of Soluble Recombinant Human CD58 (LFA-3) Molecules” Develop. Biol. Standard vol. 77:87-92, 1992.
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy,” Nature 337:525-531 (1989).
Gregersen et al., “A CD4:immunoglobulin fusion protein with antiviral effects aganist HIV,” Arch. Virol. 111:29-43 (1990).
Zettlmeissl et al, “Expression and characterization of human CD4:immunoglobulin fusion proteins,” DNA and Cell Biol. 9:347-353 (1990).
Ellis et al., “Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes,” N. Engl. J. Med. 345:248-255 (2001).
U.S. Appl. No. 08/459,350, filed Jun. 2, 1995, Wallner et al.
Abraham et al., “Expression and Function of Surface Antigens on Scleroderma Fibroblasts”Arthritis and Rheumatism34(9):1164-1172, 1991.
Altman et al., “Transfection of Genes For Cell Surface Products Involved in Antigen Presentation-Applications to the Understanding of Autoimmunity”Autoimmunity7:213-220, 1990.
Baadsgaard et al., “Psoriac Epidermal Cells Demonstrate Increased Numbers and Function of Non-Langerhans Antigen-presenting Cells”J. Invest. Dermatol. 92:190-195; 1989.
Baadsgaard, O. et al., J. Invest. Dermat. 92(2): 190-195, 1989.
Barbosa et al. (1986) Gene Mapping and Somatic Cell Hybrid Analysis of the Role of Human Lymphocyte Function-Associated Antigen-3 (LFA-3) In CTL-Target Cell Interactions:J. Immunol.136:3085-3091.
Bierer and Burakoff (1988) “T Cell Adhesion Molecules” FASEB J. 2:2584-2590.
Bierer et al. (1988) “Expression of the T-Cell Surface Molecule CD2 and an Epitope-Loss CD2 Mutant to Define the Role of Lymphocyte Function-Associated Antigen 3 (LFA-3) in T-Cell Activation”Proc. Natl. Acad. Sci. USA85:1194-1198.
Bierer et al. (1989) “A Monoclonal Antibody to LFA-3, the CD2 Ligand, Specifically Immobilizes Major Histocompatibility Complex Proteins”Eur. J. Immunol.19:661-665.
Bockenstedt et al. (1988) “The CD2 Ligand LFA-3 Activates T Cells But Depends on the Expression and Function of the Antigen Receptor” J. Immunol. 141:1904-1911.
Bromberg et al. (1991) “Anti-CD2 Monoclonal Antibodies Alter Cell-Mediated Immunity In Vivo”Transplantation51:219-225.
Brown et al. (1987) T2.2 Characterization of CD2 Epitopes By Western Blotting: inLeukocyte Typing III, A.J. McMichael (ed.) Oxford, England: Oxford University Press, 110-112.
Brown et al. (1989) “The CD2 Antigen Associates With The T-Cell Antigen Receptor CD3 Antigen Complex on the Surface of Human T Lymphocytes” Nature 339:551-553.
Chang et al. (1992) “T-Cell Activation is Potentiated by Cytokines Released by Lesional Psoriatic, but not Normal, Epidermis” Arch. Dermatol. 128:1478.
Chin, Y.H. et al. J. Invest. Dermatol. 93(2) Supplemental: 82S-87S (1989).
Clayton et al. (1987) “Murine and Human T11 (CD2) cDNA Sequences Suggest a Common Signal Transduction Mechanism” Eur. J. Immunol. 17: 1367-1370.
Conti and Cosimi (1990) “Effect of Monoclonal Antibodies on Primate Allograft Rejection” Crit. Rev. Immunol. 10(2): 113-130.
Cooper (1990) “Immunoregulation in the Skin” Current Problems in Dermatology 19:69-80.
Cooper (1992) “Skin-infiltrating Lymphocytes in Normal and Disordered Skin: Activation Signals and Functional Roles in Psoriasis and Mycosis Fungoides-type Cutaneous T Cell Lymphoma” J. Dermatol. 19:731-737.
Cooper et al. (1985) Effects of ultraviolet radiation on human epidermal cell alloantigen presentation; initial depression of langerhans cell-dependent function is followed by appearance of T6-Dr+ cells that enhance epidermal alloantigen presentation: J. Immunol. 134: 129-137.
Cunningham and Harris (1992) Antibody engineering—how to be human: TIBTECH 10:112-113.
Curtis and Barnes (1992) “The Nature of Science” in Biology, 5thed. (Worth Publishers, Inc.): 14-15.
Denning et al. (1987) Monoclonal Antibodies to CD2 and Lymphocyte Function-Associated Antigen 3 Inhibit Human Thymic Epithelial Cell-Dependent Cell-Dependent Mature Thymocyte Activation: J. Immunol. 139: 2573-2578.
Denning et al. (1988) &#
Cooper Kevin D.
Wallner Barbara P.
Astellas US LLC
Gambel Phillip
Leydig Voit & Mayer Ltd
The Regents of the University of Michigan
LandOfFree
Methods of treating skin conditions using inhibitors of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating skin conditions using inhibitors of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating skin conditions using inhibitors of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2780713